Myriad Genetics Q3 revenue $202.7 million vs. IBES estimate $191.3 million
MYGN•Myriad Genetics reported Q3 revenue of $202.7 million, compared with the IBES estimate of $191.3 million. Adjusted operating expenses were $149.9 million, gross margin was 67.9%, operating income was negative $39.9 million and operating expenses were $177.6 million.
1. Q3 results
Myriad Genetics reported Q3 revenue of $202.7 million versus the IBES estimate of $191.3 million. Adjusted operating expenses were $149.9 million, gross margin was 67.9%, operating income was negative $39.9 million and operating expenses were $177.6 million.
